What question did this study set out to answer?

The aim is to determine the prevalence and risk factors for chemotherapy-induced nausea and vomiting in breast cancer patients.

April 3, 2026Open Access

Prevalence and risk factors for nausea and vomiting in breast cancer patients undergoing chemotherapy

YFYuhui FengUniversity of South China LWLiushan WeiUniversity of South China QZQinhong ZouLanzhou University Second Hospital

Key Points

The aim is to determine the prevalence and risk factors for chemotherapy-induced nausea and vomiting in breast cancer patients.
Conducted a meta-analysis focusing on the Asian population.
Identified risk factors including younger age, history of motion sickness, and number of chemotherapy cycles.
Analyzed data related to chemotherapy-induced nausea and vomiting.
High prevalence of chemotherapy-induced nausea and vomiting among breast cancer patients identified.
Younger age, history of motion sickness, and three or more chemotherapy cycles are significant risk factors.
Targeting identified risk factors may offer potential prevention strategies.

Abstract

This meta-analysis shows that the prevalence of CINV in BC patients is high. It focused on the Asian population and indicated that younger age, history of motion sickness, and more chemotherapy cycles (≥ 3) were risk factors for CINV. Targeting these risk factors may help prevent CINV in BC patients.

Ask AI

Helpful

Bookmark

View Full Paper